Skip to main content

Adenoma clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • VT3989 in Patients With Metastatic Solid Tumors

    open to eligible people ages 18 years and up

    This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

    San Francisco, California and other locations

Our lead scientists for Adenoma research studies include .

Last updated: